Clinical trialPhase 2 / Phase 3Active not recruiting
Nordic Pancreatic Cancer Trial (NorPACT) - 1
Nordic Multicentre Un-blinded Phase II Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected
- Outcome
- Ongoing
- Phase
- Phase 2 / Phase 3
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- September 2016
- Expected end
- 30 April 2026
- Enrollment
- 140 participants
- Sites
- 13
- Primary outcomes
- Overall survival 18 month after randomization
- Sponsor
- Other
- Results posted
- No
- Last update
- 20 November 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 2
- Registry-listed results paperNeoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomi… DOI 10.1016/s2468-1253(23)00405-3↗
- Builds on itNeoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (… DOI 10.1186/s12893-017-0291-1↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.